Brief: Aim Immunotech Announces Positive Data From Phase 1 Study Evaluating Ampligen
11/04/2022 12:11
April 11 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES POSITIVE DATA FROM PHASE 1 STUDY
EVALUATING AMPLIGEN® FOR THE TREATMENT OF STAGE 4 METASTATIC
TRIPLE NEGATIVE BREAST CANCER
* AIM- PHASE1 STUDY OF METASTATIC TRIPLE-NEGATIVE BREAST
CANCER
USING CKM THERAPY, INCLUDING AMPLIGEN & PEMBROLIZUMAB,
SUCCESSFULLY MET PRIMARY ENDPOINT
Source text for Eikon: ID:nGNE5tlDn6
Further company coverage: AIM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential